Pragya TiwariShreya ThakkarLaurent Dufosséa Department of Biotechnology,Yeungnam University,Gyeongsan,Republic of Koreab Department of Biotechnology and Bioengineering,Institute of Advanced Research,Gandhinagar,Indiac Laboratoire CHEMBIOPRO (Chimie et Biotechnologie des Produits Naturels),ESIROI Département agroalimentaire,Université de La Réunion,Saint-Denis,France

Abstract:The rapid increase in antimicrobial resistance (AMR) projects a "global emergency" and necessitates a need to discover alternative resources for combating drug-resistant pathogens or "superbugs." One of the key themes in "One Health Concept" is based on the fact that the interconnected network of humans, the environment, and animal habitats majorly contribute to the rapid selection and spread of AMR. Moreover, the injudicious and overuse of antibiotics in healthcare, the environment, and associated disciplines, further aggravates the concern. The prevalence and persistence of AMR contribute to the global economic burden and are constantly witnessing an upsurge due to fewer therapeutic options, rising mortality statistics, and expensive healthcare. The present decade has witnessed the extensive exploration and utilization of bio-based resources in harnessing antibiotics of potential efficacies. The discovery and characterization of diverse chemical entities from endophytes as potent antimicrobials define an important yet less-explored area in natural product-mediated drug discovery. Endophytes-produced antimicrobials show potent efficacies in targeting microbial pathogens and synthetic biology (SB) mediated engineering of endophytes for yield enhancement, forms a prospective area of research. In keeping with the urgent requirements for new/novel antibiotics and growing concerns about pathogenic microbes and AMR, this paper comprehensively reviews emerging trends, prospects, and challenges of antimicrobials from endophytes and their effective production via SB. This literature review would serve as the platform for further exploration of novel bioactive entities from biological organisms as "novel therapeutics" to address AMR.

Genome mining and prospects for antibiotic discovery

Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?

The re-emerging role of microbial natural products in antibiotic discovery

Genome mining for the search and discovery of bioactive compounds: The Streptomyces paradigm

Using bacterial genomes and essential genes for the development of new antibiotics

Engineering fungal secondary metabolism: a roadmap to novel compounds.

Bacterial Natural Product Drug Discovery for New Antibiotics: Strategies for Tackling the Problem of Antibiotic Resistance by Efficient Bioprospecting

Genome mining for new enediyne antibiotics

Mining biology for antibiotic discovery

Targeting Bacterial Genomes for Natural Product Discovery

Alternative natural sources for a new generation of antibacterial agents

Genome Mining as New Challenge in Natural Products Discovery

The Science of Antibiotic Discovery

New antibiotics from bacterial natural products

Targeted Genome Mining—From Compound Discovery to Biosynthetic Pathway Elucidation

Strategies to access biosynthetic novelty in bacterial genomes for drug discovery

Harnessing Gram‐negative bacteria for novel anti‐Gram‐negative antibiotics

Bioprospecting for Antibacterial Drugs: a Multidisciplinary Perspective on Natural Product Source Material, Bioassay Selection and Avoidable Pitfalls

The “Three Cs” of Novel Antibiotic Discovery and Production through Synthetic Biology: Biosynthetic Gene Clusters, Heterologous Chassis, and Synthetic Microbial Consortia

Antimicrobials from endophytes as novel therapeutics to counter drug-resistant pathogens

Recent advances in genome mining and synthetic biology for discovery and biosynthesis of natural products